News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Positive Phase III Results Of Genentech (RHHBY)’s Actemra (Tocilizumab) For The Treatment Of Giant Cell Arteritis Published In The New England Journal of Medicine



7/27/2017 7:42:44 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
  • Fifty-six percent of patients treated with subcutaneous Actemra weekly with a steroid taper phase achieved steroid-free disease remission at one year, versus 14 percent in the placebo plus 26-week steroid taper group1
  • Actemra is the first FDA-approved treatment for adults with giant cell arteritis (GCA), which has had no new treatments in more than 50 years

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that data from the Phase III GiACTA study, which evaluated Actemra® (tocilizumab) in adult patients with GCA, were published in the July 27, 2017 issue of the New England Journal of Medicine.

The primary endpoint of the study was met; Actemra combined with a 26-week steroid taper regimen showed superiority in achieving sustained remission at 52 weeks (56 percent [Actemra-weekly group; p<0.0001] and 53.1 percent [Actemra-biweekly group; p<0.0001]) compared to placebo combined with a 26-week steroid taper regimen (14 percent).1

The study also met its key secondary endpoint, demonstrating that Actemra combined with a 26-week steroid taper regimen showed superiority in achieving sustained remission at 52 weeks (56 percent [Actemra-weekly group; p<0.0001] and 53.1 percent [Actemra-biweekly group; p=0.0002]) compared to placebo combined with a 52-week steroid taper regimen (17.6 percent).1

No new safety signals were observed1 and the safety profile of the Actemra groups was generally consistent with the documented safety profile of Actemra in other indications.

“The publication of these Phase III results in the New England Journal of Medicine validates the significance of our considerable basic and clinical autoimmune disease research in medical practice,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “The data from GiACTA supported the FDA approval of the first new treatment option for patients with GCA in more than 50 years, and we are committed to continuing to explore new treatment options for autoimmune diseases with significant unmet medical need.”

In May 2017, the FDA approved Actemra subcutaneous injection for the treatment of GCA. Actemra is the first therapy approved by the FDA for the treatment of adult patients with GCA. This is the sixth FDA approval for Actemra since the medicine was launched in 2010.

About the GiACTA study

GiACTA is a Phase III, global, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of subcutaneous Actemra as a novel treatment for GCA. It is the first successful clinical trial ever conducted in GCA and the first to use blinded, variable-dose, variable-duration steroid regimens. The multicenter study was conducted in 251 patients across 76 sites in 14 countries. The primary and key secondary endpoints were evaluated at 52 weeks.

Data from the Phase III GiACTA study in patients with GCA showed:

  • Actemra, initially combined with a six-month steroid (glucocorticoid) regimen, more effectively sustained remission through 52 weeks (56 percent in the Actemra weekly group and 53.1 percent in the Actemra biweekly group) compared to placebo combined with a 26-week steroid taper (14 percent) (p<0.0001).1
  • Actemra, initially combined with a six-month steroid (glucocorticoid) regimen, more effectively sustained remission through 52 weeks (56 percent in the Actemra weekly group and 53.1 percent in the Actemra biweekly group) compared to placebo combined with a 52-week steroid taper (17.6 percent).
  • Fewer patients reported serious adverse events (SAEs) in the Actemra weekly (15 percent) and biweekly groups (14.3 percent) than in the placebo combined with a 26-week steroid taper regimen (22 percent) and placebo combined with a 52-week steroid taper regimen groups (25.5 percent).1

About Giant Cell Arteritis

GCA, also known as temporal arteritis (TA), affects an estimated 228,000 people over the age of 50 in the United States, and the disease is two to three times more likely to affect women than men.2,3 GCA is often difficult to diagnose because of the wide and variable spectrum of signs and symptoms. GCA can cause severe headaches, jaw pain and visual symptoms and if left untreated, can lead to blindness, aortic aneurysm or stroke.3 Treatment to date for people with GCA has been limited to high-dose steroids that play a role as an effective ‘emergency’ treatment option to prevent damage such as vision loss.3 Due to the variability of symptoms, complexity of the disease and disease complications, people with GCA are often seen by several physicians including rheumatologists, ophthalmologists and neurologists.

About Actemra

Actemra is the first humanized interleukin-6 (IL-6) receptor antagonist approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have used one or more disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX), that did not provide enough relief. The extensive Actemra RA IV clinical development program included five Phase III clinical studies and enrolled more than 4,000 people with RA in 41 countries. The Actemra RA subcutaneous clinical development program included two Phase III clinical studies and enrolled more than 1,800 people with RA in 33 countries. In addition, Actemra is also used as an IV formulation for patients with active polyarticular juvenile idiopathic arthritis (PJIA) or systemic juvenile idiopathic arthritis (SJIA) two years of age and older. Actemra is not approved for subcutaneous use in people with PJIA or SJIA. It is not known if Actemra is safe and effective in children with PJIA or SJIA under two years of age or in children with conditions other than PJIA or SJIA.

Actemra is intended for use under the guidance of a healthcare practitioner.

Important Safety Information

Actemra can cause serious side effects. Actemra changes the way a patient’s immune system works. This can make a patient more likely to get infections or make any current infection worse. Some people taking Actemra have died from these infections.

Actemra can cause other serious side effects. These include:

  • Stomach tears
  • Changes in blood test results, including low neutrophil (white blood cells) and platelet (platelets help the blood to clot) counts, and increases in certain liver function test levels and blood cholesterol levels
  • An increased risk of certain cancers by changing the way a patient’s immune system works
  • Hepatitis B infection
  • Serious allergic reactions, including death. These may happen with Actemra infusions or injections, even if they did not occur with an earlier infusion or injection.
  • Nervous system problems

Patients should not receive Actemra if they are allergic to Actemra or if they have had a bad reaction to Actemra previously.

Common side effects in patients treated with Actemra:

Patients should tell their doctor if they have these or any other side effect that bothers them or does not go away:

  • Upper respiratory tract infections (like common cold and sinus infections)
  • Headache
  • Increased blood pressure (also called hypertension)
  • Injection site reactions

Actemra & pregnancy:

Patients should tell their doctor if they are planning to become pregnant, are pregnant, plan to breastfeed, or are breastfeeding. The patient and their doctor should decide if the patient will take Actemra or breastfeed. Patients should not do both. If a patient is pregnant and taking Actemra, they should join the pregnancy registry. To learn more, patients should call 1-877-311-8972 or talk to their doctor to register.

Patients should tell their doctor right away if they are experiencing any side effects. Report side effects to the FDA at 1-800-FDA-1088 or http://www.FDA.gov/medwatch. Report side effects to Genentech at 1-888-835-2555.

Please visit http://www.actemra.com for the full Prescribing Information, including Boxed Warning and Medication Guide, for additional Important Safety Information or call 1-800-ACTEMRA (228-3672).

Actemra is part of a co-development agreement with Chugai Pharmaceutical Co. and has been approved in Japan since June 2005. Actemra is approved in the European Union, where it is known as RoActemra, and several other countries, including China, India, Brazil, Switzerland and Australia.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

References

  1. Stone JH, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017; 377:317-28.
  2. Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States, Part II. Arthritis Rheum. 2008; 58: 26-35.
  3. Bhat S, et al. Giant cell arteritis. Midlife and Beyond, GM. Rheumatology. February 2010; 071-079.

Genentech
Media Contact:
Allison Neves, 650-467-6800
or
Investor Contact:
Neera Dahiya Ravindran, M.D., 650-491-5281


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES